We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+30.59%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2B
AUM Growth
+$56.4M
Cap. Flow
+$172M
Cap. Flow %
8.6%
Top 10 Hldgs %
60.79%
Holding
62
New
5
Increased
3
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
ZFOX
ZeroFox Holdings, Inc. Common Stock
ZFOX
+$150M
2
GOSS icon
Gossamer Bio
GOSS
+$43M
3
ALLK
Allakos
ALLK
+$16.7M
4
NOTE
FiscalNote
NOTE
+$14.2M
5
TUYA
Tuya Inc
TUYA
+$7.95M

Top Sells

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$27.2M
2
PANW icon
Palo Alto Networks
PANW
+$17M
3
VTGN icon
VistaGen Therapeutics
VTGN
+$14.3M
4
MILE
Metromile, Inc. Common Stock
MILE
+$8.61M
5
GLBE icon
Global E Online
GLBE
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 66.51%
2 Technology 14.18%
3 Industrials 9.57%
4 Consumer Staples 8.54%
5 Communication Services 1.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTIC
26
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$21.5M 1.07%
3,685,683
-4,361,545
-54% -$27.2M
IVA
27
Inventiva
IVA
$1.13B
$19.9M 0.99%
5,572,953
– –
STSA
28
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$18.9M 0.94%
3,142,958
– –
ADAP
29
DELISTED
Adaptimmune Therapeutics
ADAP
$18.4M 0.92%
17,082,612
– –
TRVI icon
30
Trevi Therapeutics
TRVI
$2.63B
$17.5M 0.87%
11,373,174
– –
OKUR
31
OnKure Therapeutics
OKUR
$168M
$16M 0.8%
478,692
– –
CSBR icon
32
Champions Oncology
CSBR
$72.1M
$12.9M 0.64%
1,713,720
– –
XFOR icon
33
X4 Pharmaceuticals
XFOR
$438M
$11.2M 0.56%
+217,439
New +$7.51M
AFMD
34
DELISTED
Affimed
AFMD
$9.12M 0.46%
442,649
– –
NOTE
35
DELISTED
FiscalNote
NOTE
$8.63M 0.43%
+141,194
New +$14.2M
BILL icon
36
BILL Holdings
BILL
$4.78B
$8.31M 0.41%
66,100
– –
SNTI icon
37
Senti Biosciences Holdings
SNTI
$11M
$8.23M 0.41%
442,973
– –
UTRS
38
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$7.96M 0.4%
500,097
– –
INZY
39
DELISTED
Inozyme Pharma
INZY
$6.55M 0.33%
2,444,379
– –
BDTX icon
40
Black Diamond Therapeutics
BDTX
$112M
$5.83M 0.29%
3,449,845
– –
LXRX icon
41
Lexicon Pharmaceuticals
LXRX
$1.1B
$5.72M 0.29%
2,382,286
– –
XERS icon
42
Xeris Biopharma Holdings
XERS
$1.37B
$5.07M 0.25%
3,246,785
– –
CBIO
43
Crescent Biopharma
CBIO
$626M
$5.01M 0.25%
90,890
– –
EAR
44
DELISTED
Eargo, Inc. Common Stock
EAR
$4.75M 0.24%
226,042
– –
TUYA
45
Tuya Inc
TUYA
$1.1B
$4.59M 0.23%
+4,934,640
New +$7.95M
SYBX
46
DELISTED
Synlogic
SYBX
$4.02M 0.2%
281,961
– –
MRKR icon
47
Marker Therapeutics
MRKR
$18.7M
$3.95M 0.2%
1,071,429
– –
LITS
48
Lite Strategy Inc
LITS
$30.9M
$3.3M 0.16%
426,654
– –
MIMO
49
DELISTED
Airspan Networks Holdings Inc
MIMO
$3.1M 0.15%
1,534,633
– –
RGLS
50
DELISTED
Regulus Therapeutics
RGLS
$2.46M 0.12%
1,445,115
– –
1
2
3

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
DF
DNCA Finance Paris, France $1.75B AUM 38.18% 1-Year Est. Return
HHAM
HITE Hedge Asset Management Braintree, Massachusetts $1.77B AUM 38.67% 1-Year Est. Return
SFI
Siemens Fonds Invest Munich, Germany $1.75B AUM 26.24% 1-Year Est. Return
VCM
Valiant Capital Management San Francisco, California $1.74B AUM 64.05% 1-Year Est. Return

NEA Management Company's Q3 2022 Portfolio in Review

As of Q3 2022, NEA Management Company held 62 positions worth $2B, up 2.9% from $1.95B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

NEA Management Company deployed $172M of net new capital in Q3 2022, opening 5 new positions and adding to 3 existing holdings. Its largest new stake was ZeroFox Holdings, Inc. Common Stock: 18,090,861 shares worth $88.3M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 69% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $27.2M trimmed.

  • NEA Management Company's largest Q3 2022 buy was ZeroFox Holdings, Inc. Common Stock: 18,090,861 shares worth $88.3M.
  • NEA Management Company added most to Allakos in Q3 2022, an estimated $16.7M increase.
  • NEA Management Company's biggest Q3 2022 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $27.2M.
  • NEA Management Company fully exited VistaGen Therapeutics in Q3 2022, selling an estimated $14.3M.
  • NEA Management Company's ten largest holdings make up 61% of its $2B portfolio in Q3 2022.
  • NEA Management Company opened 5 new positions and closed 5 in Q3 2022.
  • NEA Management Company's portfolio value rose 2.9% quarter-over-quarter to $2B.

Based on NEA Management Company's 13F filing for Q3 2022, filed 14 Nov 2022.